First reversal agent available for non-coumarin oral anticoagulant

Idarucizumab (Praxbind) rapidly reverses the anticoagulant effect of dabigatran (Pradaxa), and can be used when an urgent procedure is required or there is uncontrolled or life-threatening bleeding.

by Moriam Adetokunboh-Ajala
 Idarucizumab binds to dabigatran approximately 300-fold more potently than dabigatran does to thrombin. | SCIENCE PHOTO LIBRARY
Idarucizumab binds to dabigatran approximately 300-fold more potently than dabigatran does to thrombin. | SCIENCE PHOTO LIBRARY

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package